A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-Blind Trial of Clopidogrel Versus Placebo in High-Risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-Dose ASA [apirin].

Trial Profile

A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-Blind Trial of Clopidogrel Versus Placebo in High-Risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low-Dose ASA [apirin].

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Clopidogrel (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Acronyms CHARISMA
  • Sponsors Sanofi-Synthelabo
  • Most Recent Events

    • 24 Sep 2009 Results of the genomics substudy were presented at the 21st Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics (TCT).
    • 01 Sep 2009 Results from a cost-effectiveness analyses were published in Value in Health 12: 872-879, No. 6, Sep 2009
    • 21 Oct 2008 New trial results published in Circulation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top